TVGN vs. SNTI, COEP, PMCB, EVAX, APTO, AIM, CHRO, BCDA, GENE, and ONVO
Should you be buying Tevogen Bio stock or one of its competitors? The main competitors of Tevogen Bio include Senti Biosciences (SNTI), Coeptis Therapeutics (COEP), PharmaCyte Biotech (PMCB), Evaxion Biotech A/S (EVAX), Aptose Biosciences (APTO), AIM ImmunoTech (AIM), Chromocell Therapeutics (CHRO), BioCardia (BCDA), Genetic Technologies (GENE), and Organovo (ONVO). These companies are all part of the "biological products, except diagnostic" industry.
Tevogen Bio (NASDAQ:TVGN) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership.
25.7% of Senti Biosciences shares are owned by institutional investors. 56.6% of Tevogen Bio shares are owned by insiders. Comparatively, 12.5% of Senti Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Tevogen Bio has higher earnings, but lower revenue than Senti Biosciences.
Tevogen Bio has a net margin of 0.00% compared to Senti Biosciences' net margin of -2,692.82%. Tevogen Bio's return on equity of -21.83% beat Senti Biosciences' return on equity.
Tevogen Bio has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Senti Biosciences has a beta of 2.88, suggesting that its stock price is 188% more volatile than the S&P 500.
Senti Biosciences received 3 more outperform votes than Tevogen Bio when rated by MarketBeat users.
In the previous week, Tevogen Bio had 4 more articles in the media than Senti Biosciences. MarketBeat recorded 5 mentions for Tevogen Bio and 1 mentions for Senti Biosciences. Tevogen Bio's average media sentiment score of 0.00 beat Senti Biosciences' score of -0.47 indicating that Tevogen Bio is being referred to more favorably in the media.
Senti Biosciences has a consensus target price of $6.00, indicating a potential upside of 1,470.68%. Given Senti Biosciences' higher possible upside, analysts clearly believe Senti Biosciences is more favorable than Tevogen Bio.
Summary
Tevogen Bio beats Senti Biosciences on 7 of the 13 factors compared between the two stocks.
Get Tevogen Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tevogen Bio Competitors List
Related Companies and Tools
